HOME >> BIOLOGY >> NEWS
Researchers at IRB Barcelona discover a new mechanism that regulates stem cell division

Errors in stem cell division can give rise to tumours. By studying stem cells in the fruit fly, scientists at the Institute for Research in Biomedicine (IRB Barcelona) have identified one of the mechanisms that govern how these cells divide. The study appears this week in the scientific journal Developmental Cell.

Stem cells have the extraordinary capacity to divide producing two very distinct cells: one retains stem cell identity and continues to undergo asymmetric division, while the other specializes for a specific function and shows limited capacity to divide. This strategy allows a single stem cell to generate great amounts of tissue during a lifetime.

To ensure the correct differential identity of the resulting cells, the complex apparatus that divides that stem cell in two must form along a pre-established axis. If this does not occur, the division may be symmetric, which will generate two identical stem cells. That is to say, instead of producing tissue, the stem cells with a "disoriented" division axis may give rise to more stem cells; this is potentially dangerous for the organism as it would lead to uncontrolled proliferation of this type of cell.

How is this danger avoided? Researchers headed by Cayetano Gonzlez, ICREA Research Professor at IRB Barcelona, have studied stem cell division and discovered that one of the key factors lies in the behaviour of the intracellular structure known as the centrosome. Most animal cells have two centrosomes before division takes place and their position governs the direction of the division. In cells that divide symmetrically (giving rise to two identical cells), the two centrosomes of cell are practically identical. Surprisingly, Gonzalez and his team found striking differences in the two centrosomes of the stem cells they were studying. One is located in a fixed position and is very active during the entire cell cycle, while the other moves around the cell before coming to a stands
'"/>

Contact: Sonia Armengou
sarmengou@pcb.ub.es
34-934-037-255
Institute for Research in Biomedicine (IRB)
5-Mar-2007


Page: 1 2

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: